Effect of the oncolytic ECHO-7 virus Rigvir ® on the viability of cell lines of human origin in vitro
Conclusions: The results suggest that Rigvir® in vitro reduces the viability of cells of human melanoma, rhabdomyosarcoma, gastric adenocarcinoma, lung carcinoma, pancreas adenocarcinoma but not in PBMC. The presence of Rigvir® in the sensitive cells was confirmed using anti-ECHO-7 antibodies. The present results suggest that a mechanism of action for the clinical benefit of Rigvir® is its cytolytic properties. The present results suggest that the effect of Rigvir® could be tested in other cancers besides melanoma. Further studies of possible Rigvir® entry receptors are needed.
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Andra Tilgase, Liene Patetko, Ilze Bl ā ķ e, Anna Ramata ‑ Stunda, M ā rti ņ š Borodu š ķ is, P ē teris Alberts Tags: Research Paper Source Type: research
More News: Adenocarcinoma | Cancer | Cancer & Oncology | Carcinoma | Gastric (Stomach) Cancer | Gastroenterology | Latvia Health | Melanoma | Pancreas | Pancreatic Cancer | Rhabdomyosarcoma | Skin Cancer | Statistics | Study